September 22, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Nitto Denko Corporation has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof. Yoshiro Niitsu of Sapporo Medical University. more info >>
ACN Newswire
 Press Release News

Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies (Sept 19, 2014)
Eisai Co., Ltd. announced today that its anti-Alzheimer's agent Aricept (donepezil hydrochloride) has received approval for a new indication for dementia with Lewy bodies (DLB) in Japan. more info >>
Plasmacluster Ion Technology Reduced Airway Inflammation in Pediatric Patients with Mild to Moderate Atopic Asthma (Sept 18, 2014)
In investigator initiated clinical research(5) commissioned by Sharp, results were obtained in exploratory analysis(6) indicating that Plasmacluster Ion technology reduced the level of airway inflammation in pediatric patients with mild to moderate atopic asthma (FeNO(7) value less than 90). more info >>
Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress (Sept 17, 2014)
Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) and lenvatinib mesylate will be presented during the 39th European Society for Medical Oncology (ESMO) Congress 2014, taking place in Madrid, Spain, from September 26 - 30. more info >>
Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines (Sept 16, 2014)
Eisai Co., Ltd. announced today that it has entered into two joint research agreements for the development of new antimalarial medicines.
more info >>

Eisai and Kyorin Enter Into Agreement Concerning Compound Library Use for the Development of New Antibacterial Agents (Sept 11, 2014)
Eisai Co., Ltd. and Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. announced today that they have entered into an agreement concerning the evaluation and use of Eisai's compound library, which includes natural products, by Kyorin with the aim of leveraging both companies' resources for the discovery of innovative new antibacterial agents.
more info >>

 Global Press Release

Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies (Sept 19, 2014)

Plasmacluster Ion Technology Reduced Airway Inflammation in Pediatric Patients with Mild to Moderate Atopic Asthma (Sept 18, 2014)

Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress (Sept 17, 2014)

Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines (Sept 16, 2014)

Eisai and Kyorin Enter Into Agreement Concerning Compound Library Use for the Development of New Antibacterial Agents (Sept 11, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)